These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7397942)

  • 21. Metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a new antitumour agent, in rats, rabbits and dogs.
    Kobari T; Iguro Y; Ujiie A; Namekawa H
    Xenobiotica; 1981 Jan; 11(1):57-62. PubMed ID: 7222730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and cytotoxicity of B.3839, a molecular combination of 5-fluorouracil and N-(2-chloroethyl)-N-nitrosourea, in a mouse model.
    Loadman PM; Bibby MC; Double JA; McElhinney RS
    Invest New Drugs; 1992 Aug; 10(3):149-58. PubMed ID: 1428724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of urokinase on the transfer of 1-hexylcarbamoyl-5-fluorouracil (HCFU) into the blood, bile and pancreatic juice].
    Kato S; Matsuno S; Kakizaki K; Fukaya Y; Akaishi S
    Gan To Kagaku Ryoho; 1985 Nov; 12(11):2134-8. PubMed ID: 4062312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity.
    Zhao D; Zhang H; Tao W; Wei W; Sun J; He Z
    Biomater Sci; 2017 Feb; 5(3):502-510. PubMed ID: 28116362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel derivatives of 5-fluorouridine and 5-fluorouracil having potent antitumor and lower immunosuppressive activities.
    Mori H; Sakamoto O; Kitaichi K; Koda A; Kita J
    Jpn J Pharmacol; 1992 Mar; 58(3):269-82. PubMed ID: 1513076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.
    Fujii S; Ikenaka K; Fukushima M; Shirasaka T
    Gan; 1978 Dec; 69(6):763-72. PubMed ID: 750271
    [No Abstract]   [Full Text] [Related]  

  • 27. Studies to increase the antitumor activity of 1-(tetrahydro-2-furanyl)-5-fluorouracil and its metabolic aspects by combined administration with L-cysteine.
    Kawabata N; Sugiyama S; Kuwamura T; Satoh T; Kitagawa H
    Jpn J Pharmacol; 1983 Aug; 33(4):735-47. PubMed ID: 6415326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Synthesis and study of the antitumor activity of glucuronide derivatives of 5-fluorouracil].
    Carissimi M; de Meglio P; Gentili P; Ravenna F
    Boll Chim Farm; 1979 Dec; 118(12):721-8. PubMed ID: 552254
    [No Abstract]   [Full Text] [Related]  

  • 29. Concentration-dependent disappearance of fluorouracil from peritoneal fluid in the rat: experimental observations and distributed modeling.
    Collins JM; Dedrick RL; Flessner MF; Guarino AM
    J Pharm Sci; 1982 Jul; 71(7):735-8. PubMed ID: 7120053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil against L1210 leukemia.
    Hoshi A; Iigo M; Nakamura A; Inomata M; Kuretani K
    Chem Pharm Bull (Tokyo); 1978 Jan; 26(1):161-5. PubMed ID: 639159
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacokinetics of 1-phthalidyl-5-fluorouracil (PH-FU)].
    Fujita H; Takao A; Okamoto M; Kimura K
    Gan To Kagaku Ryoho; 1986 Jun; 13(6):2199-207. PubMed ID: 3717964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of intraperitoneal infusion 5-fluorouracil and mitomycin-C.
    Gyves J
    Semin Oncol; 1985 Sep; 12(3 Suppl 4):29-32. PubMed ID: 3931225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of capecitabine.
    Reigner B; Blesch K; Weidekamm E
    Clin Pharmacokinet; 2001; 40(2):85-104. PubMed ID: 11286326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of two new metabolites of 1-hexylcarbamoyl-5-fluorouracil in biomedical specimens by high-performance liquid chromatography.
    Kono A; Hara Y; Eguchi S; Tanaka M; Matsushima Y
    J Chromatogr; 1980 Apr; 182(1):125-9. PubMed ID: 7380898
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.
    Fujii S; Kitano S; Ikenaka K; Fukushima M; Nakamura H; Maehara Y; Shirasaka T
    Gan; 1980 Feb; 71(1):100-6. PubMed ID: 6769735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmaco-dynamic influence under ascites or laparotomy on intraperitoneal sequential MTX/5-FU therapy].
    Maruyama M; Irie T; Yoshida T; Nagahama T; Sugano N; Ebuchi M
    Gan To Kagaku Ryoho; 1998 Jul; 25(9):1439-41. PubMed ID: 9703848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
    Myers CE; Young RC; Chabner BA
    Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potentiation of the antitumor effect of 5-fluorouracil by some nucleotides, and their possible role in the potentiation.
    Tezuka M; Tamemasa O
    Jpn J Exp Med; 1983 Jun; 53(3):155-63. PubMed ID: 6663806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dihydrofluorouracil, a fluorouracil catabolite with antitumor activity in murine and human cells.
    Diasio RB; Schuetz JD; Wallace HJ; Sommadossi JP
    Cancer Res; 1985 Oct; 45(10):4900-3. PubMed ID: 3928143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.